Top Markets
Coin of the day
Chimeric Therapeutics Limited Chimeric Therapeutics Limited

Chimeric Therapeutics Limited

CHM
Clasificación en acciones #38385
Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical... Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical firm dedicated to developing and commercializing a diverse array of cell therapies designed to combat various cancers. Its lead natural killer (NK) cell platform, CHM 0201, is currently undergoing Phase I clinical evaluation for both solid tumors and hematological malignancies. Another key candidate, CHM 1101 (a CLTX CAR T therapy), is also in Phase I trials, specifically targeting recurrent or progressive glioblastoma in patients expressing MMP2+. Beyond these, the company's development pipeline encompasses CHM 0301 for blood cancers; CLTX CAR NK (CHM 1301) and CDH17 CAR NK (CHM 2301) for solid tumors. The CLTX CAR T platform (CHM 1101) is additionally being investigated for melanoma, colorectal, and prostate cancers, while CDH17 CAR T (CHM 2101) is being developed for neuroendocrine, colorectal, pancreatic, and gastric cancers. Chimeric Therapeutics, headquartered in Carlton, Australia, was founded in 2020.
Precio por acción
$0.02468497
Capitalización bursátil
$1.01M
Cambio (1 día)
-12.50%
Cambio (1 año)
-87.34%
País
AU
Comercio Chimeric Therapeutics Limited (CHM)

Categoría

Historial del precio de la acción de Chimeric Therapeutics Limited (CHM)
Precio más alto de cierre: $0.03 el 2026-08-01

Precio más bajo de cierre: $25.86 el 2021-01-01
Historial del precio de la acción de Chimeric Therapeutics Limited desde 2021 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2026 (TTM) -34.08%
2025 -54.71%
2024 -76.43%
2023 -64.94%
2022 -69.66%
2021 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
$505.24 29.45%
US
$846.09 29.68%
NL
$731.69 7.13%
CH
$1.07K -6.40%
KR
$251.82 11.25%
BE